Maine will receive a small portion of a $612 million national settlement with the pharmaceutical company Amgen Inc. over allegations that the company manipulated the prices of certain drugs.
The state will receive $13,313 in the settlement, according to a press release from the Maine Attorney General’s Office.
Through complaints in multiple states, the government alleged that Amgen illegally marketed certain drugs, paid kickbacks to health care providers to choose their drugs for Medicaid recipients, knowingly reported inaccurate average sales prices for certain drugs and knowingly reported inaccurate best prices for certain drugs.
In addition to the national settlement, the company — which produces drugs including Aranesp, Enbrel and Neulasta — will enter an agreement with the U.S. Department of Health and Human Services to monitor its marketing and sales practices.
